JP6176849B2 - アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 - Google Patents

アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 Download PDF

Info

Publication number
JP6176849B2
JP6176849B2 JP2013524738A JP2013524738A JP6176849B2 JP 6176849 B2 JP6176849 B2 JP 6176849B2 JP 2013524738 A JP2013524738 A JP 2013524738A JP 2013524738 A JP2013524738 A JP 2013524738A JP 6176849 B2 JP6176849 B2 JP 6176849B2
Authority
JP
Japan
Prior art keywords
antibody
preparation
protein
arginine
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013524738A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2013012022A1 (ja
Inventor
大介 亀岡
大介 亀岡
誠也 安武
誠也 安武
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of JPWO2013012022A1 publication Critical patent/JPWO2013012022A1/ja
Application granted granted Critical
Publication of JP6176849B2 publication Critical patent/JP6176849B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2013524738A 2011-07-19 2012-07-19 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 Active JP6176849B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011157654 2011-07-19
JP2011157654 2011-07-19
PCT/JP2012/068276 WO2013012022A1 (ja) 2011-07-19 2012-07-19 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017115935A Division JP6469765B2 (ja) 2011-07-19 2017-06-13 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤

Publications (2)

Publication Number Publication Date
JPWO2013012022A1 JPWO2013012022A1 (ja) 2015-02-23
JP6176849B2 true JP6176849B2 (ja) 2017-08-09

Family

ID=47558197

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013524738A Active JP6176849B2 (ja) 2011-07-19 2012-07-19 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
JP2017115935A Active JP6469765B2 (ja) 2011-07-19 2017-06-13 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017115935A Active JP6469765B2 (ja) 2011-07-19 2017-06-13 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤

Country Status (4)

Country Link
US (2) US9574005B2 (enExample)
EP (1) EP2735315B1 (enExample)
JP (2) JP6176849B2 (enExample)
WO (1) WO2013012022A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6176849B2 (ja) 2011-07-19 2017-08-09 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
US20160250329A1 (en) * 2013-10-29 2016-09-01 Albumedix A/S Antibody composition
CN106029682B (zh) * 2013-12-27 2021-04-13 中外制药株式会社 等电点低的抗体的纯化方法
TWI694836B (zh) * 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
MA54716A (fr) 2014-10-23 2021-11-17 Amgen Inc Réduction de la viscosité de formulations pharmaceutiques
AR104050A1 (es) * 2015-03-26 2017-06-21 Chugai Pharmaceutical Co Ltd Proceso de producción con iones de cobre controlados
ES3036076T3 (en) 2015-04-14 2025-09-12 Chugai Pharmaceutical Co Ltd Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
WO2016167263A1 (ja) 2015-04-14 2016-10-20 中外製薬株式会社 Ｉｌ－３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
WO2017057644A1 (ja) * 2015-09-30 2017-04-06 持田製薬株式会社 高濃度抗体含有液体製剤
MA43734A (fr) 2016-03-03 2018-11-28 Regeneron Pharma Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3
JP7377596B2 (ja) * 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
JOP20190255A1 (ar) 2017-04-28 2019-10-27 Amgen Inc صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
SG11201909955XA (en) 2017-05-02 2019-11-28 Merck Sharp & Dohme Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
NZ770284A (en) 2018-05-10 2025-11-28 Regeneron Pharma High concentration vegf receptor fusion protein containing formulations
EP3876990A4 (en) 2018-11-07 2023-09-06 Merck Sharp & Dohme LLC CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
US20200369760A1 (en) * 2019-05-24 2020-11-26 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-angptl3 antibodies
EP3763356A1 (en) * 2019-07-12 2021-01-13 Ludwig-Maximilians-Universität München Excipient for biotherapeutics
BR112022006590A2 (pt) * 2019-11-20 2022-06-28 Chugai Pharmaceutical Co Ltd Preparação contendo anticorpos
JP2025078889A (ja) * 2022-02-03 2025-05-21 天野エンザイム株式会社 酵素製剤
WO2025186423A1 (en) 2024-03-07 2025-09-12 Csl Behring Ag Immunoglobulin composition and method of generating an aerosol

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
JPS6013718A (ja) * 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst Ｂ型肝炎ワクチン
JPS60193925A (ja) * 1984-03-13 1985-10-02 Chemo Sero Therapeut Res Inst 凍結乾燥製剤化ワクチン
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
JP2942412B2 (ja) * 1991-12-26 1999-08-30 鐘紡株式会社 化粧料
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
EP0770628B9 (en) 1994-07-13 2007-02-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
MX9800684A (es) 1995-07-27 1998-04-30 Genentech Inc Formulacion de proteinas liofilizadas isotonicas estables.
IL129164A (en) 1996-09-26 2007-05-15 Chugai Pharmaceutical Co Ltd An antibody against peptides associated with human parathyroid hormone
UA76934C2 (en) 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
JP3998419B2 (ja) 1998-04-03 2007-10-24 中外製薬株式会社 ヒト組織因子（ｔｆ）に対するヒト型化抗体およびヒト型化抗体の作製方法
TWI242043B (en) 2000-03-10 2005-10-21 Chugai Pharmaceutical Co Ltd Polypeptide inducing apoptosis
WO2002013860A1 (en) 2000-08-11 2002-02-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
EP1327680B1 (en) 2000-10-20 2008-04-02 Chugai Seiyaku Kabushiki Kaisha Modified tpo agonist antibody
US20040156835A1 (en) 2001-05-30 2004-08-12 Taiji Imoto Protein preparation
WO2003068259A1 (fr) * 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
JP4083634B2 (ja) 2002-07-11 2008-04-30 旭化成ファーマ株式会社 光に安定なカルシトニン水溶液
JP3976257B2 (ja) 2002-09-17 2007-09-12 栄研化学株式会社 蛋白質の安定化方法
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
EP1652925B1 (en) 2003-07-15 2010-12-08 Chugai Seiyaku Kabushiki Kaisha IgM PRODUCTION BY TRANSFORMED CELLS AND METHODS FOR QUANTIFYING SAID IgM PRODUCTION
EP1908482B1 (en) * 2005-06-10 2017-09-06 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
WO2007076062A2 (en) 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
DK2006381T3 (en) 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
JP2007332093A (ja) * 2006-06-16 2007-12-27 Apro Life Science Institute Inc タンパク質のリフォールディング添加剤及びそれを用いたタンパク質の再生方法
CN101600457B (zh) 2007-01-09 2014-01-08 惠氏公司 抗il-13抗体调配物和其用途
AU2008232903B9 (en) * 2007-03-30 2013-09-05 Medimmune Llc Antibodies with decreased deamidation profiles
JP5119545B2 (ja) * 2007-06-19 2013-01-16 国立大学法人 筑波大学 蛋白質を含む液状組成物中における蛋白質の安定化方法
RU2505603C2 (ru) 2007-09-26 2014-01-27 Чугаи Сейяку Кабусики Кайся Антитело против рецептора il-6
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
MX337081B (es) 2007-12-05 2016-02-10 Chugai Pharmaceutical Co Ltd Anticuerpo anti-nr10 y su uso.
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2009104369A1 (ja) 2008-02-22 2009-08-27 パナソニック株式会社 血漿に含まれる成分の検出方法ならびにそれに用いられる試薬および検出デバイス
TWI505838B (zh) 2010-01-20 2015-11-01 Chugai Pharmaceutical Co Ltd Stabilized antibody solution containing
JP2013525484A (ja) 2010-05-03 2013-06-20 ジェネンテック， インコーポレイテッド タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
JP6176849B2 (ja) 2011-07-19 2017-08-09 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤

Also Published As

Publication number Publication date
JPWO2013012022A1 (ja) 2015-02-23
EP2735315B1 (en) 2019-10-02
US9574005B2 (en) 2017-02-21
US20170112930A1 (en) 2017-04-27
EP2735315A1 (en) 2014-05-28
JP6469765B2 (ja) 2019-02-13
WO2013012022A1 (ja) 2013-01-24
JP2017222654A (ja) 2017-12-21
US10898572B2 (en) 2021-01-26
US20140206845A1 (en) 2014-07-24
EP2735315A4 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
JP6469765B2 (ja) アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
US20230277442A1 (en) Solution preparation containing stabilized antibody
JP5906067B2 (ja) 高濃度抗体含有溶液製剤
HK1224947A (en) Solution preparation containing stabilized antibody
HK1224947A1 (en) Solution preparation containing stabilized antibody
HK1177684A (en) Liquid preparation containing stabilized antibody
HK1177684B (en) Liquid preparation containing stabilized antibody
HK1231734B (zh) 含高浓度抗体的溶液制剂

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170113

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170613

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170620

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170705

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170710

R150 Certificate of patent or registration of utility model

Ref document number: 6176849

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250